| Ytd | -13.82% | |
| 1y | -0.27% |
| Open | 4.77 | Prev Close | 5.15 | Low | 3.72 | High | 4.77 | Mkt Cap | 38.11M |
| Vol | 2.21M | Avg Vol | 186.09K | EPS | -1.91 | P/E | -1.96 | Forward P/E | -1.36 |
| Beta | 1.40 | Short Ratio | 2.29 | Inst. Own | 36.75% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 4.83 | 200-d Avg | 4.31 | 1yr Est | 11.75 |
PYPD News
Gainers China Pharma Holding (AMEX:CPHI) shares increased by 713.2% to $7.4 during Tuesday's re
HC Wainwright & Co. analyst Brandon Folkes reiterates PolyPid (NASDAQ:PYPD) with a Buy and ma
PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceut
Israeli biotech PolyPid said on Tuesday it had agreed a deal with Azurity Pharmaceuticals to commer
PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 mi
PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceu
PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceut
PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceut
HC Wainwright & Co. analyst Brandon Folkes reiterates PolyPid (NASDAQ:PYPD) with a Buy and ma
PolyPid (NASDAQ:PYPD) reported quarterly losses of $(0.41) per share which missed the analyst consen
PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma com
Roth Capital analyst Boobalan Pachaiyappan maintains PolyPid (NASDAQ:PYPD) with a Buy and lowers
PolyPid (NASDAQ:PYPD) reported quarterly losses of $(0.37) per share which beat the analyst consensu
On Thursday, 369 companies hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.
During Thursday's session, 406 companies made new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.
Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earn